Logo image of SKIN

BEAUTY HEALTH CO/THE (SKIN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SKIN - US88331L1089 - Common Stock

1.51 USD
-0.02 (-1.31%)
Last: 12/22/2025, 8:14:36 PM
1.51 USD
0 (0%)
After Hours: 12/22/2025, 8:14:36 PM
Fundamental Rating

2

Taking everything into account, SKIN scores 2 out of 10 in our fundamental rating. SKIN was compared to 36 industry peers in the Personal Care Products industry. The financial health of SKIN is average, but there are quite some concerns on its profitability. SKIN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SKIN has reported negative net income.
SKIN had a positive operating cash flow in the past year.
In the past 5 years SKIN reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: SKIN reported negative operating cash flow in multiple years.
SKIN Yearly Net Income VS EBIT VS OCF VS FCFSKIN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

SKIN has a worse Return On Assets (-2.33%) than 61.11% of its industry peers.
With a Return On Equity value of -17.89%, SKIN is not doing good in the industry: 63.89% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -2.33%
ROE -17.89%
ROIC N/A
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKIN Yearly ROA, ROE, ROICSKIN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

SKIN has a Gross Margin of 66.57%. This is comparable to the rest of the industry: SKIN outperforms 47.22% of its industry peers.
SKIN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SKIN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
SKIN Yearly Profit, Operating, Gross MarginsSKIN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SKIN has been increased compared to 1 year ago.
Compared to 1 year ago, SKIN has a worse debt to assets ratio.
SKIN Yearly Shares OutstandingSKIN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M
SKIN Yearly Total Debt VS Total AssetsSKIN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

SKIN has an Altman-Z score of -0.11. This is a bad value and indicates that SKIN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SKIN (-0.11) is worse than 80.56% of its industry peers.
The Debt to FCF ratio of SKIN is 10.65, which is on the high side as it means it would take SKIN, 10.65 years of fcf income to pay off all of its debts.
SKIN's Debt to FCF ratio of 10.65 is in line compared to the rest of the industry. SKIN outperforms 58.33% of its industry peers.
SKIN has a Debt/Equity ratio of 5.53. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 5.53, SKIN is not doing good in the industry: 86.11% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 5.53
Debt/FCF 10.65
Altman-Z -0.11
ROIC/WACCN/A
WACC6.63%
SKIN Yearly LT Debt VS Equity VS FCFSKIN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

SKIN has a Current Ratio of 4.98. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
SKIN's Current ratio of 4.98 is amongst the best of the industry. SKIN outperforms 91.67% of its industry peers.
A Quick Ratio of 4.07 indicates that SKIN has no problem at all paying its short term obligations.
SKIN's Quick ratio of 4.07 is amongst the best of the industry. SKIN outperforms 91.67% of its industry peers.
Industry RankSector Rank
Current Ratio 4.98
Quick Ratio 4.07
SKIN Yearly Current Assets VS Current LiabilitesSKIN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

SKIN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.18%.
SKIN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.15%.
Measured over the past years, SKIN shows a quite strong growth in Revenue. The Revenue has been growing by 8.72% on average per year.
EPS 1Y (TTM)-30.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-13.15%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-10.34%

3.2 Future

Based on estimates for the next years, SKIN will show a very strong growth in Earnings Per Share. The EPS will grow by 33.71% on average per year.
The Revenue is expected to grow by 1.40% on average over the next years.
EPS Next Y54.41%
EPS Next 2Y22.72%
EPS Next 3Y0.56%
EPS Next 5Y33.71%
Revenue Next Year-9.62%
Revenue Next 2Y-2.91%
Revenue Next 3Y-0.95%
Revenue Next 5Y1.4%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SKIN Yearly Revenue VS EstimatesSKIN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2032 100M 200M 300M 400M 500M
SKIN Yearly EPS VS EstimatesSKIN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SKIN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SKIN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKIN Price Earnings VS Forward Price EarningsSKIN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, SKIN is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.64
EV/EBITDA N/A
SKIN Per share dataSKIN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.72%
EPS Next 3Y0.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SKIN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BEAUTY HEALTH CO/THE

NASDAQ:SKIN (12/22/2025, 8:14:36 PM)

After market: 1.51 0 (0%)

1.51

-0.02 (-1.31%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-10 2026-03-10/amc
Inst Owners88.14%
Inst Owner Change5.04%
Ins Owners11.44%
Ins Owner Change10.21%
Market Cap192.53M
Revenue(TTM)301.92M
Net Income(TTM)-11.74M
Analysts51.43
Price Target1.97 (30.46%)
Short Float %15.24%
Short Ratio16.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)62.73%
Min EPS beat(2)-30.18%
Max EPS beat(2)155.64%
EPS beat(4)3
Avg EPS beat(4)47.59%
Min EPS beat(4)-30.18%
Max EPS beat(4)155.64%
EPS beat(8)7
Avg EPS beat(8)51.89%
EPS beat(12)10
Avg EPS beat(12)48.9%
EPS beat(16)13
Avg EPS beat(16)418.68%
Revenue beat(2)2
Avg Revenue beat(2)1.95%
Min Revenue beat(2)0.99%
Max Revenue beat(2)2.9%
Revenue beat(4)4
Avg Revenue beat(4)4.15%
Min Revenue beat(4)0.99%
Max Revenue beat(4)6.94%
Revenue beat(8)6
Avg Revenue beat(8)2.34%
Revenue beat(12)7
Avg Revenue beat(12)-0.39%
Revenue beat(16)11
Avg Revenue beat(16)2.61%
PT rev (1m)-7.2%
PT rev (3m)1.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.52%
EPS NY rev (1m)33.33%
EPS NY rev (3m)47.37%
Revenue NQ rev (1m)-0.99%
Revenue NQ rev (3m)-0.19%
Revenue NY rev (1m)0.96%
Revenue NY rev (3m)0.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.64
P/FCF 5.64
P/OCF 4.97
P/B 2.93
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)0.27
FCFY17.72%
OCF(TTM)0.3
OCFY20.13%
SpS2.37
BVpS0.51
TBVpS-0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.33%
ROE -17.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.57%
FCFM 11.3%
ROA(3y)-3.53%
ROA(5y)-10.89%
ROE(3y)-66.06%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5YN/A
F-Score6
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 5.53
Debt/FCF 10.65
Debt/EBITDA N/A
Cap/Depr 20.73%
Cap/Sales 1.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.98
Quick Ratio 4.07
Altman-Z -0.11
F-Score6
WACC6.63%
ROIC/WACCN/A
Cap/Depr(3y)42.98%
Cap/Depr(5y)45.87%
Cap/Sales(3y)3.35%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y54.41%
EPS Next 2Y22.72%
EPS Next 3Y0.56%
EPS Next 5Y33.71%
Revenue 1Y (TTM)-13.15%
Revenue growth 3Y8.73%
Revenue growth 5YN/A
Sales Q2Q%-10.34%
Revenue Next Year-9.62%
Revenue Next 2Y-2.91%
Revenue Next 3Y-0.95%
Revenue Next 5Y1.4%
EBIT growth 1Y16.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year144.46%
EBIT Next 3Y34.45%
EBIT Next 5Y34.66%
FCF growth 1Y335.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.03%
OCF growth 3YN/A
OCF growth 5YN/A

BEAUTY HEALTH CO/THE / SKIN FAQ

Can you provide the ChartMill fundamental rating for BEAUTY HEALTH CO/THE?

ChartMill assigns a fundamental rating of 2 / 10 to SKIN.


Can you provide the valuation status for BEAUTY HEALTH CO/THE?

ChartMill assigns a valuation rating of 2 / 10 to BEAUTY HEALTH CO/THE (SKIN). This can be considered as Overvalued.


Can you provide the profitability details for BEAUTY HEALTH CO/THE?

BEAUTY HEALTH CO/THE (SKIN) has a profitability rating of 1 / 10.